|
|
Cat. No. 198 308 |
50 µg purified recombinant IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
Applications | |
Clone | Gp126G12 |
Subtype | IgG2 (κ light chain) |
Immunogen | Recombinant protein corresponding to residues near the amino-terminus of mouse GAD1. (UniProt Id: P48318) |
Epitop |
AA 94 to 101 from mouse GAD1 (UniProt Id: P48318) |
Reactivity |
Reacts with: mouse (P48318), rat (P18088). Other species not tested yet. |
Remarks |
This antibody is a chimeric antibody based on the monoclonal mouse antibody 126G12. The constant regions of the heavy and light chains have been replaced with guinea pig specific sequences. Therefore, the antibody can be used with standard anti-guinea pig secondary reagents. The antibody has been expressed in mammalian cells. |
Data sheet | 198_308.pdf |
|
The glutamic acid decarboxylases GAD1 and GAD2, also referred to as GAD67, and GAD65 respectively, synthesize γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Therefore, GADs are widely used markers for the GABAergic system (1). The hydrophilic GAD1 can heterodimerize with the membrane achored GAD2 and a part of GAD1 is targeted to inhibitory nerve terminals by this mechanism (2). Although both proteins exhibit significant differences in their N-terminus they share high homology in the rest of the molecule (3).
GAD1 and 2 also occur in rodent pancreatic islets of Langerhans, whereas human islets mainly express GAD2 which has been identified as a major autoantigen in type 1 diabetes (3).